ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

Clinical Biomarker Discovery Initiative would speed progress in early detection and measurement of response to therapy, Leland Hartwell tells NCI.

November 12, 2004

Coalition Demands Role In Deciding spending will Target Healy, Broder, Chabner

October 16, 1992

2018 State of Cancer Care in America

February 3, 2022

President Accepts Rauscher Resignation

October 1, 1976

Clinical Trials: NCI Forms Panel To Help Implement Recommendations

December 12, 1997

In Brief: Kansas to Provide State Funds For Cancer Center; Meeting On Freestanding Centers In Philadelphia

May 22, 1987